Evidence map›Paper›PMID 32236310›Full record

ArticleArchives of endocrinology and metabolism2020

Diagnostic value of urinary luteinizing hormone levels in the monitoring of precocious puberty treatment.

Özge Yüce, Aysun Bideci, Nurullah Çelik, Orhun Çamurdan, Peyami Cinaz

Open access · diamondAbstract read
In one paragraph

Article in Archives of endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Özge YüceYenimahalle Training and Research Hospital, Faculty of Medicine, Yildirim Beyazit University, Ankara, Turkey.
Aysun BideciDepartment of Pediatric Endocrinology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Nurullah ÇelikDepartment of Pediatric Endocrinology, Faculty of Medicine, Cumhuriyet University, Turkey.
Orhun ÇamurdanDepartment of Pediatric Endocrinology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Peyami CinazDepartment of Pediatric Endocrinology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Gazi University · TRAnkara Yıldırım Beyazıt University · TRSivas Cumhuriyet Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective To determine whether first-voided urinary LH (FV-ULH) - level measurement can adequately assess pubertal suppression as much as standard tests can. Subjects and methods The study group included patients with central precocious puberty and rapidly progressing early puberty who received up to 3 - 4 doses of GnRHa therapy monthly and did not have adequate hormonal suppression after GnRH stimulation (90-minute LH level > 4 IU/L). Design: All of the participants underwent an LHRH test just after admission to the study. According to the stimulated peak LH levels, the patients were divided into 2 groups and followed until the end of the first year of treatment. The concordance between FV-ULH and stimulated LH levels was assessed. Results The FV-ULH levels in patients with inadequate hormonal suppression were significantly high compared to patients with adequate hormonal suppression. FV-ULH levels were very strongly correlated with stimulated LH levels (r = 0.91). Its correlation with basal LH levels was significant (r = 0.65). However, this positive correlation was modestly weakened after the first year of treatment. The cutoff value for FV-ULH of 1.01 mIU/mL had the highest sensitivity (92.3%) and specificity (100%). Conclusion FV-ULH levels, using more reliable and sensitive assay methods, can be used to monitor the adequacy of GnRHa therapy.

Indexed as

ChildFemaleGonadotropin-Releasing HormoneHumansLeuprolideLuteinizing HormoneMaleProspective StudiesPuberty, PrecociousROC CurveSensitivity and SpecificityTreatment OutcomeTriptorelin PamoateGonadotropin-Releasing HormoneLeuprolideLuteinizing HormoneTriptorelin Pamoate

Identifiers

PMID32236310
PMCPMC10118943
OpenAlexW3014998420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.